S&P 500   5,115.27 (+0.37%)
DOW   38,996.43 (+0.00%)
QQQ   443.05 (+0.92%)
AAPL   178.20 (-1.41%)
MSFT   413.01 (-0.15%)
META   499.28 (+1.87%)
GOOGL   137.78 (-0.49%)
AMZN   177.94 (+0.67%)
TSLA   200.88 (-0.50%)
NVDA   819.31 (+3.56%)
NIO   5.84 (+1.57%)
AMD   198.98 (+3.35%)
BABA   74.89 (+1.16%)
T   16.96 (+0.18%)
F   12.50 (+0.48%)
MU   95.60 (+5.51%)
CGC   3.27 (-0.61%)
GE   158.44 (+0.99%)
DIS   111.41 (-0.15%)
AMC   4.42 (+2.31%)
PFE   26.56 (+0.00%)
PYPL   60.64 (+0.50%)
XOM   106.18 (+1.59%)
S&P 500   5,115.27 (+0.37%)
DOW   38,996.43 (+0.00%)
QQQ   443.05 (+0.92%)
AAPL   178.20 (-1.41%)
MSFT   413.01 (-0.15%)
META   499.28 (+1.87%)
GOOGL   137.78 (-0.49%)
AMZN   177.94 (+0.67%)
TSLA   200.88 (-0.50%)
NVDA   819.31 (+3.56%)
NIO   5.84 (+1.57%)
AMD   198.98 (+3.35%)
BABA   74.89 (+1.16%)
T   16.96 (+0.18%)
F   12.50 (+0.48%)
MU   95.60 (+5.51%)
CGC   3.27 (-0.61%)
GE   158.44 (+0.99%)
DIS   111.41 (-0.15%)
AMC   4.42 (+2.31%)
PFE   26.56 (+0.00%)
PYPL   60.64 (+0.50%)
XOM   106.18 (+1.59%)
S&P 500   5,115.27 (+0.37%)
DOW   38,996.43 (+0.00%)
QQQ   443.05 (+0.92%)
AAPL   178.20 (-1.41%)
MSFT   413.01 (-0.15%)
META   499.28 (+1.87%)
GOOGL   137.78 (-0.49%)
AMZN   177.94 (+0.67%)
TSLA   200.88 (-0.50%)
NVDA   819.31 (+3.56%)
NIO   5.84 (+1.57%)
AMD   198.98 (+3.35%)
BABA   74.89 (+1.16%)
T   16.96 (+0.18%)
F   12.50 (+0.48%)
MU   95.60 (+5.51%)
CGC   3.27 (-0.61%)
GE   158.44 (+0.99%)
DIS   111.41 (-0.15%)
AMC   4.42 (+2.31%)
PFE   26.56 (+0.00%)
PYPL   60.64 (+0.50%)
XOM   106.18 (+1.59%)
S&P 500   5,115.27 (+0.37%)
DOW   38,996.43 (+0.00%)
QQQ   443.05 (+0.92%)
AAPL   178.20 (-1.41%)
MSFT   413.01 (-0.15%)
META   499.28 (+1.87%)
GOOGL   137.78 (-0.49%)
AMZN   177.94 (+0.67%)
TSLA   200.88 (-0.50%)
NVDA   819.31 (+3.56%)
NIO   5.84 (+1.57%)
AMD   198.98 (+3.35%)
BABA   74.89 (+1.16%)
T   16.96 (+0.18%)
F   12.50 (+0.48%)
MU   95.60 (+5.51%)
CGC   3.27 (-0.61%)
GE   158.44 (+0.99%)
DIS   111.41 (-0.15%)
AMC   4.42 (+2.31%)
PFE   26.56 (+0.00%)
PYPL   60.64 (+0.50%)
XOM   106.18 (+1.59%)
NASDAQ:MNOV

MediciNova (MNOV) Stock Price, News & Analysis

$1.36
+0.01 (+0.70%)
(As of 11:10 AM ET)
Today's Range
$1.33
$1.36
50-Day Range
$1.28
$1.65
52-Week Range
$1.26
$2.66
Volume
29,874 shs
Average Volume
60,779 shs
Market Capitalization
$66.68 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

MediciNova MarketRank™ Stock Analysis

Analyst Rating
N/A
Upside/​Downside
N/A
Short Interest
Bearish
0.54% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.97mentions of MediciNova in the last 14 days
Based on 4 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($0.34) to ($0.35) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

0.11 out of 5 stars

Medical Sector

951st out of 957 stocks

Pharmaceutical Preparations Industry

437th out of 440 stocks


MNOV stock logo

About MediciNova Stock (NASDAQ:MNOV)

MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. It is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological and other disorders, such as primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction, as well as prevention of acute respiratory distress syndrome, and long COVID. The company's product pipeline also includes MN-221 (bedoradrine), a selective beta-2-adrenergic receptor agonist for the treatment of acute exacerbations of asthma; MN-001 (tipelukast), an orally bioavailable small molecule compound to treat fibrotic and other diseases, including nonalcoholic fatty liver disease and idiopathic pulmonary fibrosis; and MN-029 (denibulin), a tubulin binding agent for treating solid tumor cancers. It has license agreements with Kyorin Pharmaceutical Co., Ltd; Angiogene Pharmaceuticals, Ltd.; and Meiji Seika Kaisha, Ltd. The company was incorporated in 2000 and is headquartered in La Jolla, California.

MNOV Stock Price History

MNOV Stock News Headlines

Medicinova Inc
The Strategic Gold Play You Haven't Heard About
Experts recommend adding gold to your portfolio, but in what form? Some savvy investors are now rejecting coins and mining stocks in favor of a unique gold investment alternative. It holds explosive growth potential similar to a junior gold stock -- but with less risk exposure.
StockNews.com Begins Coverage on MediciNova (NASDAQ:MNOV)
Bezos and Gates Invest in Search for Tech's Best-Kept Secret
Billionaires who've made their fortunes in tech, are quietly investing in essential yet rare elements known as "The Seeds of Technology". Learn more about this massive rare earth treasure hunt and the very elements making emerging technologies possible.
MediciNova Receives Gene Therapy Milestone Payment
See More Headlines
Receive MNOV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for MediciNova and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
8/09/2023
Today
3/01/2024
Next Earnings (Estimated)
5/09/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:MNOV
Employees
13
Year Founded
2000

Profitability

Net Income
$-8,560,000.00
Pretax Margin
-856.80%

Debt

Sales & Book Value

Annual Sales
$1 million
Book Value
$1.27 per share

Miscellaneous

Free Float
40,757,000
Market Cap
$66.23 million
Optionable
Optionable
Beta
0.75

Social Links

Growth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.

Get This Free Report

Key Executives

  • Dr. Yuichi Iwaki M.D. (Age 74)
    Ph.D., Co-Founder, President, CEO & Executive Director
    Comp: $933.05k
  • Dr. Kazuko Matsuda M.D. (Age 58)
    M.P.H., Ph.D., Chief Medical Officer & Director
    Comp: $653.65k
  • Dr. David H. Crean M.B.A. (Age 59)
    Ph.D., Chief Business Officer
  • Mr. John O'Neil CPA
    Controller














MNOV Stock Analysis - Frequently Asked Questions

How have MNOV shares performed in 2024?

MediciNova's stock was trading at $1.50 at the beginning of 2024. Since then, MNOV stock has decreased by 10.0% and is now trading at $1.35.
View the best growth stocks for 2024 here
.

When is MediciNova's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024.
View our MNOV earnings forecast
.

How were MediciNova's earnings last quarter?

MediciNova, Inc. (NASDAQ:MNOV) issued its earnings results on Wednesday, August, 9th. The biopharmaceutical company reported ($0.06) earnings per share for the quarter, topping the consensus estimate of ($0.07) by $0.01.

What other stocks do shareholders of MediciNova own?
Who are MediciNova's major shareholders?

MediciNova's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Barclays PLC (0.19%), Bank Julius Baer & Co. Ltd Zurich (0.04%), Simplex Trading LLC (0.00%) and Concourse Financial Group Securities Inc. (0.00%).
View institutional ownership trends
.

How do I buy shares of MediciNova?

Shares of MNOV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:MNOV) was last updated on 3/1/2024 by MarketBeat.com Staff